Health Reference LibraryInositol dosage and timing: how to run a fair test
This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.
Summary
The research regimen is simple: 2 to 4g of myo-inositol per day, split into a morning and an evening dose, held steady for at least 12 weeks. In 500mg capsules that is 4 to 8 capsules daily, 2 to 4 at each end of the day. Start at 2g for the first fortnight, then step up to 4g if wanted; digestive effects only appear in trials from 12g per day, three times the top of this range. Review at week 12, the point standalone trials measured, and at week 24 for cycle and insulin-resistance outcomes. Anyone with diagnosed PCOS or on glucose-lowering therapy sets this plan with their GP first.
How it works
Inositol is classed as an insulin-sensitising agent (Carlomagno 2011), and the regimen follows from that: steady daily intake over months, because the markers it may move, insulin resistance and menstrual pattern, are measured over 12 to 24 week windows in trials, never over days.
Effective dose
The studied range is 2 to 4g of myo-inositol per day. Standalone trials in the systematic review behind the 2023 PCOS guideline typically used around 2g daily for 12 weeks (Fitz 2024); the 2024 phase III trial used 600mg twice daily alongside metformin for 24 weeks (Cureus 2024). In 500mg capsules the arithmetic is 4 capsules for 2g and 8 capsules for 4g. There is no established benefit to exceeding 4g for the uses most buyers have in mind, and no UK reference intake exists because the body synthesises its own.
Forms compared
Run the test on myo-inositol, the form carrying most of the trial base. The separate buying guide in this library compares myo-inositol and D-chiro-inositol and explains why myo is the default.
Timing
Split the daily total into a morning and an evening dose, with or without food, the pattern the trials used. Clock precision does not matter; missing days does. If building to 4g, hold 2g for the first fortnight and step up once settled.
Safety profile
The safety review found digestive effects, mainly nausea, wind and loose stools, only from 12g per day, with a maximum tolerated dose in trials of 18g (Carlomagno 2011). The full protocol range of 2 to 4g sits at a third of the level where effects began, and trial adverse events at these intakes were mild and uncommon.
Special populations
Diagnosed PCOS: set the plan with your GP, because the strongest recent trial used inositol alongside metformin under clinical care (Cureus 2024) and the 2023 international guideline is candid that inositol alone offers limited clinical benefit. Pregnancy: discuss any supplement with your midwife or GP before starting. Glucose-lowering therapy of any kind: GP or pharmacist first.
Interactions
The one standing caution is glucose-lowering therapy, because stacking insulin-sensitising agents belongs under clinical supervision, which is exactly how the phase III trial did it. No food or mineral separation rules apply, so inositol slots into a routine without rearranging iron, zinc or anything else.
Guideline positions
Fitz 2024, the systematic review behind the 2023 International PCOS Guideline: standalone trials typically 2g daily for 12 weeks; evidence limited and inconclusive, to be weighed openly between patient and clinician. Cureus 2024 phase III: 600mg myo-inositol twice daily with metformin over 24 weeks, cycle outcomes read at 12 and 24 weeks, insulin resistance at week 24. Carlomagno 2011: digestive effects from 12g per day, maximum tolerated dose 18g.
Practical framework
Run it in four steps. One, qualify: a trial makes sense for someone wanting to test the metabolic and cycle-support uses with honest expectations, and belongs with a GP first for diagnosed PCOS, pregnancy or any glucose-lowering prescription. Two, dose: 2g daily in two doses for a fortnight, then 2 to 4g held steady; with 500mg capsules that is 4 to 8 per day. Three, monitor: nothing is judged before week 12; the week 12 read covers cycles and how you feel, and week 24 is the firmer read the phase III trial used. Four, the branch: consistent use to 24 weeks with nothing to show is a real answer, and the next step is a GP conversation, not a higher dose. A clean single-ingredient option is myo-inositol in 500mg capsules at nutritailor.co.uk/products/inositol.
Common misconceptions
That the dose needs calculating per body weight: the trial range is a flat 2 to 4g daily. That more works faster: benefits came at 2 to 4g and digestive effects start at 12g, so escalation buys side effects, not speed. That timing is delicate: morning and evening with or without food is the whole rule, and consistency over weeks is what the trials actually tested.
Sources
- Fitz V, Graca S, Mahalingaiah S, et al 2024. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology and Metabolism 109(6):1630, PMID 38163998.
- Multicentre phase III investigators (India), Eris Lifesciences sponsored 2024. A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome. Cureus, December 2024, PMID 39803009.
- Carlomagno G, Unfer V 2011. Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences 15(8):931-936, PMID 21845803.